Conventional induction treatments do not influence overall survival in multiple myeloma

Mario Boccadoro, Antonio Palumbo, Chiara Argentino, Alida Dominietto, Roberto Frieri, Giuseppe Avvisati, Benedetto Comotti, Vito Michele Lauta, Marina Liberati, Filippo Marmont, Pellegrino Musto, Maurizio Tribalto, Alessandro Pileri

Research output: Contribution to journalArticlepeer-review

Abstract

A retrospective analysis was performed on two subsequent myeloma patient series treated with the same conventional induction treatments, melphalan and prednisone or alternating VMCP/VBAP: 273 were enrolled in the multicentre M83 trial (M83 trial group) from 1983 to 1986; 160 were referred to a single institution (Haemat.To group) from 1986 to 1994. Response to treatment was very similar in the two groups (53% v 50.3%). Remission duration curves merely overlapped (median 20 v 21 months). However, overall survival was significantly longer in the Haemat.To group (43.2 v 33 months, P <0.04). This difference was due to a prolonged period from relapse or progression to death (21 v 8 months, P <0.01; 20.8 v 7 months, P <0.009). Prolonged survival was also observed in poor-prognosis patients with a serum β 2-microglobulin level > 3 mg/l, in the Haemat.To group (31.8 v 24.2 months, P <0.04). The same induction treatments produced almost identical response rate and remission duration in both groups, but overall survival was 10 months longer for one group. However, it could be argued that treatment salvage modalities and support therapies have been improved in a decade. Lastly, induction treatments did not influence overall survival.

Original languageEnglish
Pages (from-to)333-337
Number of pages5
JournalBritish Journal of Haematology
Volume96
Issue number2
Publication statusPublished - 1997

Keywords

  • chemotherapy
  • multiple myeloma
  • overall survival
  • remission duration

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Conventional induction treatments do not influence overall survival in multiple myeloma'. Together they form a unique fingerprint.

Cite this